Articles tagged with: Revlimid
News»
On Monday, Onyx Pharmaceuticals agreed to purchase Proteolix, the developer of the cancer drug carfilzomib (Kyprolis), for $276 million. Carfilzomib, which is Proteolix’s leading cancer drug, has demonstrated significant tumor-reduction activity in Phase 1 trials of patients with relapsed multiple myeloma.
Similar to Velcade (bortezomib), carfilzomib is a proteasome inhibitor that blocks the activity of these protein-destroying enzymes and induces cancer cell death. Carfilzomib is currently undergoing Phase 2 trials on patients with relapsed multiple myeloma, for which data will be reported in late 2010. Phase 3 trials combining carfilzomib with
News»
Researchers at St George’s, University of London have developed a new directory that could lead to quicker and more targeted treatment for multiple myeloma and other cancer patients.
The directory identifies 40,000 genes that can cause cancer and lists the effects on each gene by three drugs used in the treatment of multiple myeloma.
The three drugs included in the directory are thalidomide (Thalomid), Revlimid (lenalidomide), and Actimid (pomalidomide, CC-4047). Both thalidomide and Revlimid are approved for the treatment of multiple myeloma. Actimid is still being tested for multiple …
News»
Researchers from the University of Athens and Penn State University have announced that in a study of newly diagnosed patients, elevated TIMP-1, a blood biomarker, correlated with more advanced multiple myeloma, poorer overall survival, and the presence of bone lesions.
TIMP-1 belongs to the family of “tissue inhibitors of metalloproteinases,” a group of proteins that help regulate bone turnover – the removal of old bone tissue (resorption) and the addition of new bone tissue (ossification). Through multiple molecular pathways, excess TIMP-1 may contribute to tumor development because it directly encourages cell growth …
NewsFlash »
FDA Grants Priority Review Status To Velcade – The U.S. Food and Drug Administration (FDA) granted priority review to the supplemental new drug application for Velcade (bortezomib) from Millennium: The Takeda Oncology Company. The supplemental new drug application includes long-term overall survival data from the Phase 3 Vista trial, which examined treatment with Velcade in patients with previously untreated multiple myeloma. Applications granted priority review are approved by the FDA within six months instead of ten. For more information, please see the Millennium press release.
Celgene To Benefit From Increased Use Of Revlimid – Analysts believe that Celgene's stock may recover by the end of this year due to more doctors treating patients with Revlimid (lenalidomide). Revlimid is becoming more accepted as a maintenance treatment for multiple myeloma, lymphoma, and leukemia. Also, Celgene will report on a new clinical trial in December, which may raise sales. For more information, please see the Forbes article.
MMRF Chicago Marathon – On October 11 the Multiple Myeloma Research Foundation (MMRF) team will be taking part in the Bank of America Chicago Marathon. The MMRF is seeking contributions for its runners, which will go towards helping to fund multiple myeloma research. For more information, please visit the MMRF Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
Research Confirms MGUS Is Linked To Myeloma, But May Not Be Linked To As Many Diseases As Previously Thought – According to a study published in the August 2009 issue of Mayo Clinic Proceedings, monoclonal gammopathy of undetermined significance (MGUS) may not be linked to as many serious diseases as previously thought. MGUS is a symptomless blood disorder that is a precursor of multiple myeloma. This study confirmed a link between MGUS and 14 diseases. However, before this study, it was also thought to be a precursor for many more diseases. These Mayo Clinic findings may save patients from unnecessary tests and treatment. For more information, please see the Mayo Clinic press release.
Lawsuit Claims Celgene Corporation Misappropriated The Idea Behind Thalidomide – On August 24, Beth R. Jacobson filed a lawsuit against Celgene Corporation claiming “misappropriation of an idea” and “unjust enrichment” concerning the company’s sale of thalidomide (Thalomid) and Revlimid (lenalidomide) for the treatment of myeloma. The suit claims that Jacobson developed the original idea for treating myeloma with thalidomide and is consequently entitled to compensation based on established legal precedent. Jacobson seeks a minimum of $300 million in past damages and 25 percent of the future profits from the sale of Celgene’s thalidomide products. For more information, please see Ms. Jacobson's press release.
Light The Night Walks – On September 11, the Leukemia & Lymphoma Society (LLS) will hold Light the Night Walks in St. Louis and St. Peters, MO. Participants will walk along a two- or three-mile route, carrying a lighted balloon, in support of those touched by blood cancer. For more information, please visit the LLS Web sites for each of the events.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
D.C. Ride-a-thon – On August 1, Jim Barth, a multiple myeloma patient, will begin his ride on his scooter from Clearwater, FL to the International Myeloma Foundation (IMF) Seminar in Washington, D.C. Jim is looking for sponsors to help raise funds for the IMF and the Tampa – St. Petersburg Multiple Myeloma Education Group. The IMF Seminar will be held on August 7 and 8. For more information, please visit Jim’s Web site. Donations may be made on his page.
5430 Long Course Triathlon – On August 9, the 5430 Long Course Triathlon will begin at 6:30 a.m. and end at 3:30 p.m. The triathlon will be held in Boulder, CO, and the Leukemia & Lymphoma Society’s Team In Training (TNT) will be participating. To join Team In Training for the Triathlon, please visit the TNT Web site.
Ontario Approves Funding For Revlimid – On July 24 the Ontario government approved funding for Revlimid (lenalidomide) to be used with dexamethasone (Decadron) for multiple myeloma patients. This makes Ontario the second Canadian province to fund Revlimid, following British Columbia. Myeloma Canada is now urging other provinces to follow the examples set by the two provinces. For more information, please visit the CNW Group Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
News»
Celgene Corporation reported yesterday that a Phase 3 clinical trial of Revlimid (lenalidomide) in first-line multiple myeloma patients has produced overwhelmingly positive results. The outcome of the trial, known as MM-015, suggests that Revlimid taken in combination with melphalan (Alkeran) and prednisone, followed by continuous Revlimid, produces significant improvement in progression-free survival.
While Revlimid is already prescribed as a front-line drug for multiple myeloma, it is approved for use only in patients for whom other treatments have failed. In the United States, it is also used off-label, meaning that …
